Article Text

other Versions

PDF
Research paper
Malformation risks of antiepileptic drug monotherapies in pregnancy: updated results from the UK and Ireland Epilepsy and Pregnancy Registers
  1. E Campbell1,
  2. F Kennedy2,
  3. A Russell3,
  4. W H Smithson4,
  5. L Parsons5,
  6. P J Morrison6,
  7. B Liggan7,
  8. B Irwin1,
  9. N Delanty8,
  10. S J Hunt1,
  11. J Craig1,
  12. J Morrow1
  1. 1Neurology Department, Belfast Health and Social Care Trust, Royal Victoria Hospital, Belfast, Co Antrim, UK
  2. 2Institute of Neurology, University College London
  3. 3Department of Clinical Neurophysiology, Institute of Neurological Sciences, Southern General Hospital, Glasgow, UK
  4. 4Academic Unit of Primary Medical Care, Samuel Fox House, University of Sheffield, Northern General Hospital, Sheffield, UK
  5. 5Neurology Department, Luton & Dunstable Hospitals NHS Trust, Luton, UK
  6. 6Department of Medical Genetics, Belfast Health and Social Care Trust, Belfast City Hospital, Belfast, Co Antrim, UK
  7. 7RSCI, Beaumont Hospital, Dublin, Ireland
  8. 8Department of Neurology, Beaumont Hospital, Dublin, UK
  1. Correspondence to Dr Jim Morrow, Department of Neurology, Belfast Health and Social Care Trust, Grosvenor Road, Belfast BT12 6BA, UK; jim.morrow{at}belfasttrust.hscni.net

Abstract

Objectives Antiepileptic drug (AED) exposure during pregnancy increases the risk of major congenital malformations (MCMs). The magnitude of this risk varies by AED exposure. Here we provide updated results from the UK Epilepsy and Pregnancy Register of the risk of MCMs after monotherapy exposure to valproate, carbamazepine and lamotrigine.

Methods Fifteen-year prospective observational study from 1996 until 2012. The main outcome measure is the MCM rate.

Results Informative outcomes were available for 5206 cases. 1290 women were exposed to valproate monotherapy, 1718 to carbamazepine monotherapy and 2198 to lamotrigine monotherapy. The MCM risk with valproate monotherapy exposure in utero was 6.7% (95% CI 5.5% to 8.3%) compared with 2.6% with carbamazepine (95% CI 1.9% to 3.5%) and 2.3% with lamotrigine (95% CI 1.8% to 3.1%). A significant dose effect was seen with valproate (p=0.0006) and carbamazepine (p=0.03) exposed pregnancies. A non-significant trend towards higher MCM rate with increasing dose was found with lamotrigine. MCM rate for high-dose lamotrigine (>400 mg daily) was lower than the MCM rate for pregnancies exposed to <600 mg daily of valproate, but this was not significant (3.4% vs 5.0%, p=0.31).

Conclusions In utero exposure to valproate carries a significantly higher MCM risk than lamotrigine (p=0.0001) and carbamazepine (p=0.0001) monotherapy. In contrast to prior findings, high-dose lamotrigine was associated with fewer MCMs than all doses of valproate. While lamotrigine has a favourable profile compared with valproate for adverse pregnancy outcomes, the requirements for seizure control should not be overlooked.

  • EPILEPSY
  • ANTICONVULSANTS

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.